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Summary Increased expression of epidermal growth factor receptor (EGFr) has been reported in non small
cell lung cancers (NSCLC) when compared to normal lung. We have examined post-operative survival in 19
surgically treated patients with NSCLC who had full characterisation of EGFr on primary tumour membrane
preparations from resection specimens. There were ten squamous, seven adeno and two large cell carcinomas.
The median concentration of high affinity sites was 31 fmol per mg of protein (4-1532) and the median
dissociation constant (Kd) of these high affinity sites was 2.3 x 10-'° per mol (1.2-30 x 10-'°). Seven patients
survived over 5 years. Twelve patients died between 8.5 and 55 months from the time of surgery. When > 5
year survivors were compared to non-survivors there was no difference as regards tumour size or stage, or as
regards age or sex. The survivors had a median concentration of high affinity EGFr sites of 16.1 fmol mg-'
protein compared to a median concentration of 68.6 fmol mg-' protein in the non-survivors (P= 0.01
Wilcoxon test). No long term survivor had >35 fmol mg- ' protein of receptor. Thus EGFr quantitation may
give independent prognostic information in NSCLC and help to select patients for adjuvant therapy after
surgery. These results need confirmation in a larger prospective study.
Epidermal growth factor (EGF) has been shown to be
mitogenic to ectodermal (Cohen & Elliott, 1963) and
endodermal (Konturek et al., 1981) cells in vivo. EGF binds
to a receptor (EGFr) which is a transmembrane protein with
an extracellular binding domain and an intracellular tyrosine
kinase domain (Carpenter, 1983). Histological study has
indicated that the EGFr may participate in EGF induced
proliferation of the conducting airways of human foetal lung
(Oliver, 1988). EGFr appears to play an important role in
the development and proliferation of some human malignan-
cies including those of neuroglia (Liberman et al., 1984),
bladder (Neal et al., 1985) and breast (Sainsbury et al., 1985).
Increased expression of EGFr appears to be particularly
common in squamous carcinomas (Hendler et al., 1988) and
we have shown by immunoperoxidase studies using a mono-
clonal antibody to EGFr that tumour cells in squamous lung
cancers have stronger staining for EGFr then other non-
small cell lung cancers (NSCLC) (Veale et al., 1987). In that
study staining in stage three NSCLC where the tumour was
locally invading or with mediastinal lymph node involvement
was greater than in stage I and II tumours with no spread
beyond the hilar nodes.
We have, in addition, shown by ligand binding studies
with 1125 radiolabelled EGF that there is increased concentra-
tion of EGFr on NSCLC compared to normal lung. We
failed to find any difference in EGFr concentration or affinity
between NSCLC of different histological type or clinical
stage in radioligand binding studies (Veale et al., 1989).
Since NSCLC with a high proportion of cells expressing
EGFr have a high rate of proliferation (Dazzi et al., 1990)
and since the latter is associated with a poor prognosis, we
have examined the prognostic significance of EGFr expres-
sion in NSCLC measured directly by ligand binding studies.
Patients and methods
The study population comprised 19 patients who underwent
surgical resection of bronchial carcinoma. Patients were of
good performance status in order to be considered for oper-
ation. The tumours included ten squamous carcinomas, seven
adenocarcinomas and two large cell carcinomas. Tumours
were staged post operatively by the tumour, nodal involve-
ment, metastasis (TNM) system on examination of resected
material (pTNM) (Mountain et al., 1974). We have used this
staging system as the tumours were resected between 1984
and 1986. By these criteriae T2 tumours are greater than
3 cm in diameter or invading the visceral pleura or there is
atalectasis of less than an entire lung. N defines nodal
invasion with NI signifying metastasis to ipsilateral hilar
nodes and N2 means mediastinal or subcarinal lymph node
involvement. EGFr binding was studied by multipoint bind-
ing assay on tumour membrane preparations as previously
reported (Veale et al., 1989).
Tumours were collected fresh at operation and stored in
sucrose buffer at - 18°C. Membranes were prepared by
homogenisation of finely cut tissue and differential centri-
fugation. The homogenate was centrifuged at 300 g at 4'C
for 40 min. The pellet obtained formed the membrane
preparation which was confirmed by 5' nucleotidase estima-
tion (Gentry & Olsson, 1975). The protein concentration of
the membrane preparation was measured by the Bradford
method (Bradford, 1976) and standardised to 1000 ygml.
The concentration of EGFr was measured by competitive
ligand binding studies using radio-iodine labelled EGF in
competition with ten to 14 varying concentrations of
unlabelled ligand (Bennet, 1978) as previously described.
Briefly, membrane preparation (0.1 ml) was incubated at
26C with 0.1 ml of 1125 labelled EGF at a final concentration
of 0.3 nM. To the incubation were added 12 to 14 varying
concentrations of unlabelled EGF (from 0 to 200 nM). The
solution was incubated at 26°C for 2 h conditions which had
been established as optimal in preliminary studies. Incuba-
tion was terminated by the addition of 1 ml of ice-cold buffer
and centrifugation at 14000g. The binding reaction was
linearly related to protein concentration up to 1.5 mgml-I.
Post operatively the patients were seen 3 monthly for the
first 6 months and thereafter annually. At each review the
patient had a clinical examination and chest radiograph. On
relapse patients were referred for radiotherapy if clinically
indicated for symptom control. One patient with disease
involving mediastinal nodes at surgery had post operative
radiotherapy to the mediastinum. The minimum follow up
period was 6 years. Patient's general practitioners were con-
tacted for details and all deceased patients had died from
recurrent disease.
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Statistical methods
The effect of age, staging, cell type, operation performed and
EGFr concentration on survival were assessed separately
using Cox's regression model. Furthermore, the effect of
EGFr expression upon survival, adjusted for each of the
other variables separately, was assessed by fitting each
variable followed by EGFr concentration into the Cox
regression model as described by Altman (1991). The Cox
regression models were implemented via the BMDP statistical
package using program 2L. It was not possible to do any
further multivariate analysis due to the small number of
subjects in the study.
Results
Nineteen tumours were examined by 10-14 point Scatchard
analysis (Scatchard, 1949) of EGFr binding and showed high
and low affinity binding sites. The median concentration of
high affinity sites was 31 fmol per mg of protein (range
4-1532) and the median dissociation constant (Kd) of these
high affinity sites was 2.3 x 10-10 per mol (1.2-30 x 10-'°).
The median concentration of low affinity sites was 255 fmol
per mg of protein (53-3892) with a median binding Kd of
1 x 10-9 (0.8 to 41).
The clinical features of the patients and tumours are
shown in Table I. The median age at operation was 60 years
(39-74). Tumour stage by the TNM system showed a
majority of patients to have large tumours T2-T3. Eleven
patients had spread to the hilar lymph nodes only (NI) and
one had involvement of mediastinal nodes (N2). No patient
showed evidence of systemic metastases at the time of
surgery.
The first patient died 7.5 months after surgery. Seven
patients have survived over 5 years from the time of oper-
ation with the longest survival to the time of data analysis
being 71 months. Twelve patients have died between 8.5 and
55 months from the time of surgery. All patients died of
metastatic disease.
When 5 year survivors were compared to non-survivors
Table I Comparison of survivors > 5 years with patients who died
<5 yrs >5 yrs
Number 12 7
Male 10 5
Age 60 (54-74) 57 (39-67)
Pneumonectomy 2 4
Lobectomy 10 3
Tumour size
T3 3 2
T2 7 5
TI 2 0
Nodes positive 8 4
Squamous 8 2
Carcinoma
Adenocarcinoma 4 3
Large cell 0 2
Differentiation
Well 7 2
Poor 5 5
Median EGFr (fmol mg') 68.6 16.1
high affinity
Range 10.5-1533 4.3-34.4
(Table I) there were no differences in tumour size, stage or
type. The two large cell cases were in the surviving group,
and ten of the 12 patients who died had a lobectomy com-
pared to three of the seven survivors. There was no difference
between the groups as regards age or sex.
The 5 year survivors had a median (range) concentration
of high affinity EGFr sites of 16.1 (4.3-34.4) fmol mg-' pro-
tein compared to a concentration of 68.6 (10.5-1533)
fmol mg-' protein in the non-survivors (P = 0.001 Wilcoxon
test). All patients with high affinity receptor concentrations
greater than 35 fmol mg-' had died within 5 years, whereas
seven of 11 patients with receptor concentrations less than
this value were still alive after 5 years (P = 0.02 Log rank
test) (Figure 1). A univariate analysis of the influence of
other prognostic factors in comparing patients with tumours
having EGFr concentration <35>fmol mg-' protein showed
72
Survival curve < 35 fmol > a
Survival and EGFR concentration
No
0
019
b
60 _
48 _
s 3
c 36
0
24 _-
12 _
0
10 20 30 40 50 60
Survival (months)
C
0
C3
0
O-
<35 fmol mg-1 >35 fmol mg -
[EGFR]
0 Squamous carcinoma
a Non-squamous carcinoma
Closed Pneumonectomy
Open Lobectomy
Figure 1 a, Log rank survival stratified by EGFr greater than 35 fmol mg-' membrane protein or less than 35 fmol mg- . Seven
patients are alive after a minimum of 5 years follow up. There were eight patients in the group with >35 fmol mg-' and 11 in the
group with <35 fmol mg'l. b, Survival vs different histological subtypes and operations, stratified by EGFr> 35 or
<35 fmol mg-' membrane protein.
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Table H Univariate Cox regression results
Variable Hazard ratio 95% C.I.for H.R. P-valve
Age 1.06 0.98, 1.15 0.12
T 0.76 0.21, 2.83 0.68
N 1.08 0.32, 3.60 0.91
Cell type 2.61 0.77, 8.81 0.12
Op. type 2.95 0.64, 13.50 0.18
EGFR 5.67 1.58, 20.38 0.008
TableIII Effect ofEGFR adjusted foreachofage, T, N, cell type and
op. type separately
Hazard ratio 95% C.Lfor H.R. P-valve
EGFR 4.75 1.28, 17.5 0.02
(age adjusted)
EGFR 5.77 1.56, 21.37 0.009
(T adjusted)
EGFR 8.59 1.83, 40.26 0.006
(N adjusted)
EGFR (cell type 6.58 1.68, 25.76 0.007
adjusted)
EGFR (op. type 4.73 1.25, 17.97 0.02
adjusted)
that no other variable significantly affected survival difference
between the two groups (Table II). The unadjusted effect of
having GFr >35 fmol mg' is to have an approximate 5-fold
increase in risk of death, as derived from a hazard ratio of
5.67 for EGFr in Table II. Adjusting the effect of EGFr
separately for each of age, T stage, N stage, cell type and
operation type leads to similar conclusions (Table III).
Discussion
We have shown that patients with non-small cell lung
tumours which have a high concentration of EGFr have a
shorter survival than those with tumours with a lower con-
centration of receptors. Over expression of EGFr in
squamous carcinoma of the head and neck has been found to
be associated with poor survival (Hendler et al., 1988). In
bladder cancer the level of EGFr is associated with the
degree of invasion and with poor differentiation (Neal et al.,
1985).
The highest concentration of receptor in the survival group
was 34.4fmolmg-' of membrane protein. If we take this
level as a cut-off point and examine survival difference
(Figure 1) there is a highly significant difference in survival
(P = 0.02). Thus this cut-off point could be used to define
prognostic groups.
One possible mechanism by which EGFr might play a role
in tumour progression is that subclones of tumour cells that
express more EGFr may be selected for growth, invasion and
metastasis. EGFr may be implicated in the growth and
spread of tumours through an autocrine mechanism whereby
tumour cells possessing receptors secrete the growth factor
which interacts with the receptor to stimulate further growth
(Sporn & Todaro, 1980). The addition of EGF to culture
medium has been shown to lead to increased growth in lung
cancers of all types (Singletary et al., 1987). Infusion of EGF
into athymic mice with implanted squamous tumours expres-
sing a high concentration of EGFr led to increased growth of
the tumours (Ozawa et al., 1987).
The results presented here are comparable to those of
Tateishi et al. who studied adenocarcinomas of the lung and
showed by immunocytochemical staining that patients with
EGFr positive tumours and strong staining for TGFa had a
significantly reduced survival compared with those with
positive EGFr and little TGFa staining (Tateishi et al., 1990).
In that study cases that demonstrated high expression of
growth factors with co-expression of receptors were in
advanced stage, which suggests an autocrine role in spread of
adenocarcinoma. TGFa binds to the EGFr with similar
actions to those on binding of EGF with its receptor
(Reynolds et al., 1981). Imanishi et al. showed that an
exogenously added monoclonal antibody against hTGFa
inhibited growth of hTGFa producing lung adenocarcinoma
cell lines in vitro (Imanishi et al., 1989).
Kern et al. using immunohistological methods showed that
pl85neu, an oncogene which encodes a protein with extensive
homology to EGFr, expression in human lung adenocar-
cinoma predicts shortened survival (Kern et al., 1990).
Dittadi et al. used a radioligand binding assay on 51
NSCLC and showed, like us, a significantly higher concen-
tration of EGFr in tumours compared to normal lung
(Dittadi et al., 1991). They found no relationship between
histology or stage and receptor concentration. They did,
however, show a trend for a relation between receptor
positivity and tumour grading in this relatively large series.
These authors concluded that there may be a possible
independent prognostic role for EGFr as we have demon-
strated here.
Radioligand binding analysis may involve examination of
non-cancerous stromal cells in contrast to immunohisto-
chemistry. It is, however, quantitative and we ensured to cut
tumour tissue from the centre of the tumour to prepare
membrane preparations. A significant correlation has been
shown between maximum binding capacities of EGFr
obtained from Scatchard plots and the percentage of positive
tumour cells obtained by immunohistochemical staining with
monoclonal antibody EGFR1 on ovarian carcinomas,
Henzen-Logmans et al. (1992).
Although this study examines a small number of cases, no
pre-selection was made to analyse these particular tumours.
None of the other prognostic studies had quantitative data
on receptors, which may be helpful in designing targeting
studies. We would emphasise that these results pertain to
small numbers of tumours and thus our results need to be
confirmed in larger prospective studies. Our study provides a
basis for carrying out a prospective study on a much larger
scale. If these results were confirmed in prospective study
then EGFr assay may be clinically useful in selecting patients
for adjuvant therapy using either chemo or radiotherapy or
new therapeutic approaches targeted at the receptor (Mul-
shine et al., 1989).
We acknowledge the helpful criticism of Dr D. Moro.
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